1 month Sarepta Therapeutics (NASDAQ:SRPT) Earns Buy Rating from Analysts at Jefferies Financial GroupMarketBeat
Jefferies Financial Group initiated coverage on Sarepta Therapeutics in a research note on Monday. They set a “buy” rating and a $165.00 price objective on the stock.
Jefferies Financial (JEF) · Nasdaq 100 · Science
X